Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nicotinamide Riboside in Combined Pulmonary Hypertension
NCT07563322Recruiting
- Sponsor
- Vanderbilt University Medical Center
- Start
- Apr 2026
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of nicotinamide riboside in pulmonary hypertension (PH) (2 arms), sponsored by Vanderbilt University Medical Center. Primary endpoints: Change in NADH:Ubiquinone Oxidoreductase Subunit B7 at 15 weeks and Change in 6-Minute Walk Distance at 15 weeks. Started Apr 2026; status: recruiting.
02
Drugs
nicotinamide riboside
03
Conditions
pulmonary hypertension (PH)
Beyond the preview
Go deeper on NCT07563322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07563322.